A human induced pluripotent stem cell model from a patient with hereditary cerebral small vessel disease carrying a heterozygous R302Q mutation in HTRA1.

"Declarations Ethics approval and consent to participatePrior informed and written consent was obtained from the patient to Niigata University. The study was approved by the Ethics Committee of Niigata University (approval no. G2017-0031) and Keio University (approval no. 20080016) regarding all experimental procedures, including blood sampling from the donor. Consent for publicationNot applicable. Competing interestsH.O. is a scientific advisory board of San Bio Co., Ltd. and K Pharma Inc. The other authors declare no competing interests. Competing interests H.O. is a scientific advisory board of San Bio Co., Ltd. and K Pharma Inc. The other authors declare no competing interests."

"Funding This study was supported by Japan Agency for Medical Research and Development (AMED) (Grant No. 19bm0804003, 20bm0804003, 21bm0804003, 20ek0109492, 21ek0109492, 22ek0109492 to H.O., and Grant No. 22bm0804027h0003 to S.M.)."